UPDATED: Alector lays off 17% of staff after AbbVie-partnered Alzheimer's asset fails phase 2
Alector’s AbbVie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study, the latest in a string of investigational meds missing the mark in the indication. | Alector’s Abbvie-partnered Alzheimer's asset has failed to slow disease progression in a phase 2 study,
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00.Don't ...
Alector's AL002 fails in Phase 2 Alzheimer's trial, halting extension study; focus shifts to other programs as workforce is ...
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for ...
BTIG analyst Thomas Shrader maintained a Buy rating on Alector (ALEC – Research Report) yesterday and set a price target of $5.00. Don't Miss our Black Friday Offers: Unlock your investing potential ...
Alector Therapeutics said that its Phase 2 trial for an experimental Alzheimer’s antibody failed, dealing a blow to what ...
On Monday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $3.96 which represents a slight increase of $0.02 or 0.51% from the prior close of $3.94. The stock opened at $4.01 and ...
Investigational simufilam failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback